A need for greater reporting of socioeconomic status and race in clinical trials

S J Lee, A Kavanaugh

Ann Rheum Dis 2004;**63**:1700–1701. doi: 10.1136/ard.2003.019588

Comprehensive data about new treatments for rheumatoid arthritis (RA), including their potential for disease remission, efficacy, and safety, are derived from clinical research. Often these studies can significantly influence management strategies for patients with RA. Virtually all recent studies on RA report disease characteristics relevant to outcome. Factors such as the presence of rheumatoid factor, the number of tender and swollen joints, measurements of acute phase reactants, the presence of radiographic erosions, and prior treatments with disease modifying antirheumatic drugs define the severity of disease, and also, the potential for responses to treatments. The age and sex of the study population are also reported in every study, although their effect on disease outcome is less clear.

However, many clinical studies, including some landmark studies that have dramatically shaped our approach to RA, fail to report other key demographic information. For example, race and socioeconomic status (SES), two potentially critical factors affecting the outcome of patients with RA, are seldom reported in publications (table 1).^{1–17} A number of studies have demonstrated that disease outcome in RA correlates inversely and strongly with SES and education.^{18–20} Although the data on RA are limited, studies in systemic lupus erythematosus and in non-rheumatological conditions have shown that race can be associated with worse disease prognosis, a more aggressive disease, and a

greater functional decline.^{21–25} Furthermore, race can influence the efficacy profile of various therapeutic agents.^{26–29} Some of the hypotheses to explain these racial differences in the prevalence of disease and the response to treatment have included genetic polymorphisms, differences in SES, and disparities in healthcare use. A better understanding of the role of race on treatment modalities will require inclusion and reporting of race in clinical studies along with subgroup analysis by race.

A heterogeneous study group that reflects the general population with RA is also important for the generalisability of clinical studies. A survey of some recently published clinical trials illustrates that, in general, minorities may be underrepresented in RA therapeutic trials (table 1). Interestingly, it has been suggested that minority patients may be less willing to participate in clinical studies owing to factors such as distrust of physicians/clinical studies, insufficient knowledge about continuing trials, and lower expectations from clinical trials.^{30–34}

In many cases, the racial composition, SES, and education may be collected but not be presented in many pivotal trials in rheumatology. Self report of race, SES, and education is inexact but can be easily performed and has been used routinely in many studies. Despite the inexactness inherent in the process, significant correlations have been noted between self reported race, ethnicity, and disease outcome.³⁵

Table 1 Demographic reporting of the study group in recent RA studies

Agent [reference]	Study group	Racial composition	SES*	Education
Rituximab ¹	22	Not reported	Not reported	Not reported
CTLA-4lg ²	214	White 194 (91%) Black 9 (4%) Other 11 (5%)	Not reported	Not reported
Etanercept ³	628	White 576 (92%) Black 18 (3%) Hispanic 15 (2%) Asian 12 (2%) Other 7 (1%)	Not reported	Not reported
SSZ+HCQ+MTX ⁴	102	Not reported	Not reported	Not reported
Leflunomide+MTX ⁵	263	White 234 (89%) Black 15 (6%) Asian 8 (3%) Other 6 (2%)	Not reported	Not reported
CSA+MTX ⁶	148	White 137 (93%) Asian 11 (7%)	Not reported	Not reported
SSZ+MTX+prednisone ⁷	155	Not reported	Not reported	Not reported
SSZ+HCQ+MTX ⁸	195	Not reported	Not reported	Not reported
Prednisone ⁹	128	Not reported	Not reported	Not reported
MTX ¹⁰	123	Not reported	Not reported	Not reported
Leflunomide ¹¹	482	Not reported	Not reported	Not reported
Leflunomide ¹²	358	Not reported	Not reported	Not reported
MTX+leflunomide ¹³	999	Not reported	Not reported	Not reported
Infliximab ¹⁴	428	White 389 (91%)	Not reported	Not reported
Etanercept+MTX ¹⁵	89	White 70 (79%)	Not reported	Not reported
Etanercept ¹⁶	633	White 544 (86%)	Not reported	Not reported
Adalimumab ¹⁷	271	Not reported	Not reported	Not reported

SES, socioeconomic status; SSZ, sulfasalazine; MTX, methotrexate; HCQ, hydroxychloroquine; CSA, ciclosporin.

Greater availability of this information, either in the publication or on line, will improve our understanding of the safety and efficacy of various therapeutic agents. Also, inclusion of racially and economically heterogeneous populations of patients with RA will increase the external validity of the trial results.

Authors' affiliations

S J Lee, A Kavanaugh, University of California, San Diego, Division of Rheumatology, Allergy, and Immunology, La Jolla, CA, USA

Correspondence to: Dr A Kavanaugh, 9320 Campus Point Dr, Suite 225, La Jolla, CA 92037-0943, USA; akavanaugh@ucsd.edu

Accepted 16 February 2004

REFERENCES

- 1 Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. *Ann Rheum Dis* 2002;**61**:883–8.
- 2 Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis. *Arthritis Rheum* 2002;**46**:1470–9.
- 3 Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. *J Rheumatol* 2001;**28**:1238–44.
- 4 O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. *N Engl J Med* 1996;**334**:1287–91.
- 5 Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. *Ann Intern Med* 2002;**137**:726–33.
- 6 Tugwell P, Pincus T, Yacum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. *N Engl J Med* 1995;**333**:137–41.
- 7 Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet* 1997;**350**:309–18.
- 8 Mottonen T, Honnonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. *Lancet* 1999;**353**:1568–73.
- 9 Kirwan J. Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. *N Engl J Med* 1995;**333**:142–6.
- 10 Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis. *Arthritis Rheum* 1994;**37**:1492–8.
- 11 Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. *Arch Intern Med* 1999;**159**:2542–50.
- 12 Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. *Lancet* 1999;**353**:259–66.
- 13 Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomar B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. *Rheumatology (Oxford)* 2000;**39**:655–65.
- 14 Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. *Lancet* 1999;**354**:1932–9.
- 15 Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* 1999;**340**:253–9.
- 16 Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *N Engl J Med* 2000;**343**:1586–93.
- 17 Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: ARMADA trial. *Arthritis Rheum* 2003;**48**:35–45.
- 18 Pincus T, Callahan LF. Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. *J Chron Dis* 1985;**38**:973–84.
- 19 Callahan LF, Pincus T. Formal education level as a significant marker of clinical status in rheumatoid arthritis. *Arthritis Rheum* 1988;**31**:1346–57.
- 20 Criswell LA, Katz PP. Relationship of education level to treatment received for rheumatoid arthritis. *J Rheumatol* 1994;**21**:2026–33.
- 21 Jordan JM. Effect of race and ethnicity on outcomes in arthritis and rheumatic conditions. *Curr Opin Rheumatol* 1999;**11**:98–103.
- 22 Halevy D, Radhakrishnan J, Appel GB. Racial and socioeconomic factors in glomerular disease. *Semin Nephrol* 2001;**21**:403–10.
- 23 Vaccarino V, Gahbauer E, Kasl SV, Charpentier PA, Acampora D, Krumholz HM. Differences between African Americans and whites in the outcome of heart failure: evidence for a greater functional decline in African Americans. *Am Heart J* 2002;**143**:1058–67.
- 24 Al-Othman MO, Morris CG, Logan HL, Hinerman RW, Amdur RJ, Mendenhall WM. Impact of race on outcome after definitive radiotherapy for squamous cell carcinoma of the head and neck. *Cancer* 2003;**98**:2467–72.
- 25 Govindarajan R, Shah RV, Erkanan LG, Hutchins LF. Racial differences in the outcome of patients with colorectal carcinoma. *Cancer* 2003;**97**:493–8.
- 26 Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. *J Am Coll Cardiol* 2003;**41**:1148–55.
- 27 Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, et al. Age-race subgroup compared with rennin profile as predictors of blood pressure response to antihypertensive therapy. *JAMA* 1998;**280**:1168–72.
- 28 Venter CP, Joubert PH. Ethnic differences in response to β -adrenoceptor blockade by propranolol. *J Cardiovasc Pharmacol* 1984;**6**:361–4.
- 29 Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men—a comparison of six antihypertensive agents with placebo. *N Engl J Med* 1993;**328**:914–21.
- 30 Shavers VL, Lynch CF, Burmeister LF. Racial differences in factors that influence the willingness to participate in medical research studies. *Ann Epidemiol* 2002;**12**:248–56.
- 31 Robertson NL. Clinical trial participation. *Cancer* 1994;**74**:2687–91.
- 32 Shavers VL, Lynch CF, Burmeister LF. Factors that influence African-Americans' willingness to participate in medical research studies. *Cancer* 2001;**91**(suppl 1):233–6.
- 33 Fouad MN, Partridge E, Wynn T, Green BL, Kohler C, Nagy S. Statewide Tuskegee Alliance for clinical trials. A community coalition to enhance minority participation in medical research. *Cancer* 2001;**91**(suppl 1):237–41.
- 34 Corbie-Smith G, Thomas S, St George D. Distrust, race, and research. *Intern Med* 2002;**162**:2458–63.
- 35 Gifford AL, Cunningham WE, Heslin KC, Andersen RM, Nakazono T, Lieu DK, et al. Participation in research and access to experimental treatments by HIV-infected patients. *N Engl J Med* 2002;**346**:1373–82.